Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
The advent of AI that leverages natural language processing might offer a breakthrough in efforts to identify novel targets for new drug development. Tokyo startup FRONTEO says its AI engine can uncover uncharted scientific connections hidden in research papers, enabling…
To read the full story
Related Article
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- FRONTEO’s AI Engine Uncovers Novel Pancreatic Cancer Targets as Company Eyes Out-Licensing
July 24, 2025
- Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
BUSINESS
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…